ADMA Biologics Inc (NASDAQ:ADMA) Director Eric I. Richman bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 9th. The shares were acquired at an average price of $2.15 per share, with a total value of $53,750.00. Following the purchase, the director now owns 31,300 shares of the company’s stock, valued at $67,295. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

ADMA Biologics Inc (NASDAQ ADMA) traded down $0.08 on Monday, reaching $2.32. The company’s stock had a trading volume of 341,800 shares, compared to its average volume of 50,811. ADMA Biologics Inc has a 52 week low of $2.01 and a 52 week high of $6.88. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Friday, August 11th. The biotechnology company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.29). The firm had revenue of $3.40 million for the quarter, compared to analyst estimates of $3.52 million. ADMA Biologics had a negative return on equity of 76.26% and a negative net margin of 35.00%. equities analysts predict that ADMA Biologics Inc will post -2.25 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “ADMA Biologics Inc (ADMA) Director Buys $53,750.00 in Stock” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/13/adma-biologics-inc-adma-director-buys-53750-00-in-stock.html.

Separately, ValuEngine cut ADMA Biologics from a “sell” rating to a “strong sell” rating in a research note on Friday, September 1st.

About ADMA Biologics

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Receive News & Ratings for ADMA Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.